Human Growth Hormone (hgh) Or Derivative Patents (Class 514/11.4)
-
Publication number: 20120177602Abstract: A pharmaceutical composition comprising a mixture of: (c) an active macromolecular principle; (d) an aromatic alcohol absorption enhancer chosen from propyl gallate, butylated hydroxy toluene (BHT), butylated hydroxy anisole (BHA) and analogues and derivatives thereof, or mixtures thereof; and (d) a biguanide or a pharmaceutically acceptable salt thereof, capable of increasing the solubility of the aromatic alcohol absorption enhancer in an aqueous medium, wherein the aromatic alcohol absorption enhancer is present in an amount by weight greater than or equal to that of the active principle.Type: ApplicationFiled: March 8, 2012Publication date: July 12, 2012Inventor: Roger R. C. NEW
-
Publication number: 20120172303Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.Type: ApplicationFiled: August 6, 2010Publication date: July 5, 2012Applicant: Novo Nordisk Health Care AGInventors: Nils Langeland Johansen, Henrik Sune Andersen, Jens Buchardt, Carsten Behrens, Leif Norskov-Lauritsen, Jing Su
-
Publication number: 20120156164Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.Type: ApplicationFiled: September 2, 2010Publication date: June 21, 2012Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Ki-Dong Park, Yoon-ki Joung, Kyung-Min Park, Eu-Gene Lih
-
Publication number: 20120149644Abstract: The present invention relates to methods of predicting the level of response to treatment with growth hormone in an individual having Growth Hormone Deficiency (GHD) or Turner Syndrome (TS).Type: ApplicationFiled: August 30, 2010Publication date: June 14, 2012Applicant: Merck Serono SAInventors: Theo Theocharis, Sylvain Larroque, Laurence Bernard
-
Publication number: 20120141410Abstract: Embodiments of the invention relate to compositions and methods of dry eye or keratoconjunctivitis sicca.Type: ApplicationFiled: September 12, 2011Publication date: June 7, 2012Applicant: INVITRX, INC.Inventor: Habib Torfi
-
Publication number: 20120132204Abstract: An inhaler includes a first body member and a second body member fit closely together to form an inhaler body, and an outlet. The first body member has a medicament chamber containing a unit dose of powdered medicament. A seal such as a foil strip seals the medicament chamber and extends outwardly of the inhaler body. In use, one end of the seal can be grasped by a user and withdrawn, fully or partially, from the inhaler body, to release the powdered medicament from the medicament chamber. The second body member includes a medicament collection well in which the medicament is collected upon its release from the medicament chamber. The medicament collection well forms part of an airway connecting into the outlet. In use, air can be drawn by inhalation at the outlet to entrain the powder medicament in the collection well for inhalation by a user.Type: ApplicationFiled: February 9, 2012Publication date: May 31, 2012Applicant: INNOVATA BIOMED LIMITEDInventors: Samuel W. Lucking, Glen P. Martyn
-
Publication number: 20120135919Abstract: A conjugate that includes a drug covalently linked to a polymer. Upon administration, the conjugate is digested by an enzyme that is present at the site of administration thereby releasing a therapeutic agent. The conjugate may demonstrate substantially the same pharmacokinetic and pharmacodynamic behavior as the drug itself. A material for controllably releasing a conjugate in response to the local concentration of a molecular indicator. The material includes a plurality of conjugates and a plurality of multivalent cross-linking agents. The polymers of the conjugates include an analog of the indicator within their covalent structure. The multivalent cross-linking agents include cross-link receptors that interact with the indicator analog and thereby cross-link the conjugates.Type: ApplicationFiled: February 6, 2012Publication date: May 31, 2012Applicant: SMARTCELLS, INC.Inventors: Thomas M. Lancaster, Matthew Nalewanski, Todd C. Zion
-
Publication number: 20120122782Abstract: Formulations and methods are provided for improving the stability upon exposure to aqueous media of polypeptides present in non-aqueous suspension vehicles. In particular aspects of the invention, formulations are provided that comprise a complex of a metal ion and a polypeptide suspended in a non-aqueous, biocompatible suspension vehicle. Aggregation of individual polypeptide molecules is reduced when aqueous media is introduced to such formulations, serving to stabilize the polypeptide.Type: ApplicationFiled: November 21, 2011Publication date: May 17, 2012Inventors: Catherine M. Rohloff, Guohua Chen, Zhongli Ding, Stephen Andrew Berry, Latha Pisharody Narayanan, Michael Desjardin
-
Patent number: 8178108Abstract: The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encoded amino acids and hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.Type: GrantFiled: October 17, 2007Date of Patent: May 15, 2012Assignee: Ambrx, Inc.Inventors: Ying Buechler, Ricky Lieu, Michael Ong, Stuart Bussell, Nick Knudsen, Ho Sung Cho
-
Patent number: 8178494Abstract: Formulations of modified growth hormone polypeptides are provided, including human growth hormone polypeptides with one or more non-naturally encoded amino acids with an increased half-life.Type: GrantFiled: October 25, 2007Date of Patent: May 15, 2012Assignee: AMBRX, Inc.Inventors: Anna-Maria Hays, Ying Buechler, David C. Litzinger
-
Publication number: 20120108512Abstract: The invention relates to stable pharmaceutical compositions comprising a therapeutic peptide derivatized with a property-modifying group, wherein the property-modifying group is conjugated to the peptide by use of a linker comprising an oxime bond.Type: ApplicationFiled: May 7, 2010Publication date: May 3, 2012Applicant: Novo Nordisk Health Care AGInventor: Mats Reslow
-
Publication number: 20120100103Abstract: Disclosed are in situ-forming injectable hydrogel and medical uses thereof. In the in situ-forming injectable hydrogel two or more homogeneous or heterogeneous polymers are bonded to each other by a dehydrogenation reaction between phenol or aniline moieties on adjacent polymers, wherein a polymer backbone is grafted with a phenol or aniline moiety using a linker. In contrast to conventional hydrogel, the in situ-forming injectable hydrogel is superior in terms of in vivo stability and mechanical strength thanks to the introduction of a water-soluble polymer as a linker which leads to an improvement in the reactivity of phenol or aniline moieties. Having the advantage of superior bio stability and mechanical strength, the hydrogel finds a variety of applications in the biomedical field.Type: ApplicationFiled: July 1, 2010Publication date: April 26, 2012Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park
-
Patent number: 8163695Abstract: Formulations of modified human growth hormone polypeptides are provided.Type: GrantFiled: October 25, 2007Date of Patent: April 24, 2012Assignee: AmbrxInventors: Anna-Maria A. Hays, Ying Buechler, David C. Litzinger
-
Patent number: 8158582Abstract: The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having an endocrine disorder characterized by partial endogenous growth hormone activity or signaling. The invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) effective to improve metabolism in the patient, where the patient receives IGF-1 in a single daily administration.Type: GrantFiled: June 1, 2006Date of Patent: April 17, 2012Assignee: Tercica, Inc.Inventors: Ross G. Clark, Gillian Clark, legal representative
-
Publication number: 20120088716Abstract: Method for increasing half-life of compounds in plasma and novel derivatives of such compounds.Type: ApplicationFiled: December 15, 2011Publication date: April 12, 2012Applicant: Novo Nordisk A/SInventors: Florencio Zaragoza Dörwald, Christine Bruun Schiødt, Thomas Kruse Hansen, Kjeld Madsen
-
Publication number: 20120088724Abstract: Formulations containing complexed human growth hormone crystals are described. Also described are needleless injection systems for crystalline proteins.Type: ApplicationFiled: October 10, 2011Publication date: April 12, 2012Applicant: Althea Technologies, Inc.Inventors: Wen-Li Chung, Lawrence Bush, Sergey Pechenov, Sujit K. Basu
-
Patent number: 8143216Abstract: Modified growth hormone polypeptide and uses thereof are provided.Type: GrantFiled: October 25, 2007Date of Patent: March 27, 2012Assignee: Ambrx, Inc.Inventors: Ho Sung Cho, Thomas O. Daniel, Richard D. DiMarchi, Anna-Maria A. Hays, Troy E. Wilson, Bee-Cheng Sim, David C. Litzinger
-
Patent number: 8143214Abstract: Protein-polymer conjugates are described. Also described are a method for preparing a protein-polymer conjugate and its use in treating hepatitis B virus or hepatitis C virus infection.Type: GrantFiled: August 15, 2008Date of Patent: March 27, 2012Assignee: PharmaEssentia Corp.Inventor: Ko-Chung Lin
-
Publication number: 20120058938Abstract: The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body. In particular, the invention concerns the use of a nutritional composition for the treatment of a disorder, which is mediated by a postprandial endocrine or neurological response in a human body, wherein the nutritional composition comprises one or more of a specific protein fraction, a specific carbohydrate fraction and a specific nutritional fiber fraction.Type: ApplicationFiled: March 9, 2010Publication date: March 8, 2012Applicant: N.V. NUTRICIAInventors: Robert Johan Joseph Hageman, Mirian Lansink
-
Publication number: 20120027690Abstract: The present document relates to a manufacturing method for pH-sensitive graft polymer micelles and a polymer micelle-type pharmaceutical composition containing the graft copolymer. The pH-sensitive graft copolymer micelles are usable as various markers and contrast agents for various molecular images for the diagnosis and treatment of diseases and a carrier for delivery of various medicines according to disease. The pH-sensitive graft copolymer forms micelles that can be used in target-oriented diagnosis and medicine release according to changes in the pH of a body. The polymer micelles are provided by inducing a graft copolymer of poly(?-amino ester) compounds which has a solubility in water depending on pH but is incapable of forming the micelles due to a self-assembly phenomenon, and hydrophilic poly(ethylene glycol) compounds.Type: ApplicationFiled: April 9, 2010Publication date: February 2, 2012Applicant: Research & Business Foundation Sungkyunkwan UniversityInventors: Doo Sung Lee, Min Sang Kim, Bong Sup Kim
-
Patent number: 8080391Abstract: The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.Type: GrantFiled: December 21, 2005Date of Patent: December 20, 2011Assignee: AMBRX, Inc.Inventors: Ying Buechler, Ricky Lieu, Michael Ong, Stuart Bussell, Nick Knudsen, Ho Sung Cho
-
Patent number: 8071544Abstract: Formulations containing complexed human growth hormone crystals are described. Also described are needleless injection systems for crystalline proteins.Type: GrantFiled: December 13, 2007Date of Patent: December 6, 2011Assignee: Althea Technologies, Inc.Inventors: Wen-Li Chung, Lawrence Bush, Sergey Pechenov, Sujit K. Basu
-
Publication number: 20110281800Abstract: The invention describes albumin fusion proteins comprising growth hormone and serum albumin. The invention also describes nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acid molecules, host cells transformed with these vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally, the invention describes compositions comprising the albumin fusion proteins, and methods of treating patients in need of growth hormone, comprising administering the albumin fusion proteins of the invention.Type: ApplicationFiled: May 22, 2009Publication date: November 17, 2011Inventor: David James Ballance
-
Publication number: 20110257098Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.Type: ApplicationFiled: November 25, 2009Publication date: October 20, 2011Applicant: MERCK SERONO S.A.Inventors: Marianne Tuefferd, Jérôme Dauvillier, Arnaud Delaye, Sonia Schnieper-Samec
-
Publication number: 20110237509Abstract: Preparations of recombinant human growth hormone (hGH) are provided having a purity that comprises 2% or less of a peptide other than native human growth hormone (e.g., essentially free of multimeric forms) are disclosed. Active pharmaceutical ingredient (API) preparations of recombinant hGH suitable for commercial production of formulation grade recombinant hGH are provided. A stable Master Cell Bank of transformed E. coli is also disclosed, as well as methods for creating a transformed E. coli preparation that includes a Met-AsphGH encoding sequence. Improved manufacturing methods are also presented that are suitable for large scale production of highly purified preparations of recombinant human growth hormone.Type: ApplicationFiled: February 17, 2011Publication date: September 29, 2011Applicant: Elona BiotechnologiesInventors: Matthew M. Skinner, Ronald Zimmerman
-
Publication number: 20110230404Abstract: Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are disclosed.Type: ApplicationFiled: January 13, 2011Publication date: September 22, 2011Applicant: OHIO UNIVERSITYInventors: Marcia J. Kieliszewski, Jianfeng Xu, John Kopchick, Shigeru Okada, Gary D. Meyer
-
Publication number: 20110230408Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.Type: ApplicationFiled: June 1, 2011Publication date: September 22, 2011Applicant: Genentech, Inc.Inventors: Barbara H. O'Connor, James Q. Oeswein
-
Publication number: 20110217376Abstract: Disclosed is a temperature- and pH-sensitive hydrogel composed of a poly(amidoamine) oligomer only. The hydrogel is prepared in a simple manner and is readily released from the body. Further disclosed are a method for preparing the hydrogel and a drug carrier using the hydrogel.Type: ApplicationFiled: November 3, 2010Publication date: September 8, 2011Applicant: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATIONInventors: Doo Sung LEE, Bong Sup KIM, Minh Khanh NGUYEN
-
Patent number: 7998930Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.Type: GrantFiled: November 3, 2005Date of Patent: August 16, 2011Assignee: HanAll BioPharma Co., Ltd.Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
-
Publication number: 20110195097Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.Type: ApplicationFiled: April 20, 2011Publication date: August 11, 2011Inventors: Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar
-
Publication number: 20110195899Abstract: Formulations of modified human growth hormone polypeptides are provided.Type: ApplicationFiled: August 5, 2010Publication date: August 11, 2011Applicant: AMBRX, INC.Inventors: Anna-Maria A. HAYS PUTNAM, Ying BUECHLER, David C. LITZINGER
-
Publication number: 20110195020Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.Type: ApplicationFiled: February 4, 2011Publication date: August 11, 2011Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20110177029Abstract: The present invention provides covalent conjugates between a polypeptide and a modifying group, such as a water-soluble polymer (e.g., PEG). The amino acid sequence of the polypeptide includes one or more O-linked glycosylation sequence, each being a substrate for a GIcNAc transferase. The modifying group is covalently linked to the polypeptide via a glycosyl-linking group interposed between and covalently linked to both the polypeptide and the modifying group. In one embodiment, a glucosamine linking group is directly attached to an amino acid residue of the O-linked glycosylation sequence. The invention further provides methods of making polypeptide conjugates. The present invention also provides non-naturally occurring polypeptides that include at least one O-linked linked glycosylation sequence of the invention, wherein each glycosylation sequence is a substrate for a GIcNAc transferase. The invention further provides pharmaceutical compositions that include a polypeptide conjugate of the invention.Type: ApplicationFiled: June 4, 2008Publication date: July 21, 2011Applicant: NOVO NORDISK A/SInventor: Shawn DeFrees
-
Patent number: 7964183Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.Type: GrantFiled: December 29, 2009Date of Patent: June 21, 2011Assignee: Intarcia Therapeutics, Inc.Inventors: Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar
-
Publication number: 20110144017Abstract: Reductive amination of peptide-derived aldehydes with anilines or heteroarylamines containing a property-modifying group provides new, hydrolytically stable protein conjugates, suitable for therapy.Type: ApplicationFiled: July 5, 2007Publication date: June 16, 2011Applicant: Novo Nordisk Health Care AGInventor: Florencio Zaragoza Dörwald
-
Patent number: 7959926Abstract: The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encoded amino acids and hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.Type: GrantFiled: October 17, 2007Date of Patent: June 14, 2011Assignee: Ambrx, Inc.Inventors: Ying Buechler, Ricky Lieu, Michael Ong, Stuart Bussell, Nick Knudsen, Ho Sung Cho
-
Publication number: 20110130331Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.Type: ApplicationFiled: January 25, 2011Publication date: June 2, 2011Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
-
Publication number: 20110123487Abstract: The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistence in the body, solubility, and bioavailability.Type: ApplicationFiled: August 6, 2010Publication date: May 26, 2011Inventor: ASHUTOSH CHILKOTI
-
Patent number: 7947473Abstract: The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encoded amino acids and hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.Type: GrantFiled: January 31, 2008Date of Patent: May 24, 2011Assignee: AMBRX, Inc.Inventors: Ying Buechler, Ricky Lieu, Michael Ong, Stuart Bussell, Nick Knudsen, Ho Sung Cho
-
Patent number: 7947304Abstract: The invention encompasses a transdermal patch formulation comprising hGH, at least one sugar, one amino acid or polyol, and a buffer, wherein the buffer maintains the pH of the formulation in the range of about 5 to about 9 and the formulation does not contain both glycine and mannitol.Type: GrantFiled: November 2, 2006Date of Patent: May 24, 2011Assignee: TransPharma Medical Ltd.Inventors: Hagit Sacks, Meir Stern
-
Publication number: 20110118183Abstract: The present invention relates to novel human growth hormone (hGH) variant(s) with one or more N-glycans. The hGH variants of the invention comprises an amino acid sequence which includes at least one N-glycosylation motif (N-X-S/T) arising from one or more mutations not present in the wild type hGH. The hGH variants of the invention have a prolonged circulatory half-life and thus can be effectively used as a protein therapeutic for disease states that will benefit from increased levels of hGH. The process of obtaining the hGH variants is also encompassed by the invention.Type: ApplicationFiled: June 26, 2009Publication date: May 19, 2011Applicant: Novo Nordisk Health Care AGInventors: Gert Bolt, Claus Kristensen, Esper Boel, Thomas Veje Lundgaard
-
Publication number: 20110112021Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: ApplicationFiled: April 29, 2009Publication date: May 12, 2011Applicant: Ascendis Pharma ASInventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
-
Publication number: 20110097367Abstract: A method of making and using a monolithic alginate implant is described. The implant is formed by providing an uncrosslinked, highly pure and high molecular weight alginate solution and injecting the alginate solution into a patient at a predetermined site to form a gel body comprising the monolithic alginate implant. Spontaneous crosslinking of the monolithic alginate implant occurs at the predetermined site without the addition of an exogenous crosslinker. The implant may be used for treating medical conditions requiring support of sphincter musculature, reconstructive surgery, or cosmetic reconstruction, for the treatment of wrinkles on the hand, face, or décolleté, or for increasing volume, for example in the case of (HIV-induced) lipoatrophy of the breasts, and for the treatment of selected diseases, including gastrooesophageal reflux disease, urinary incontinence or vesicoureteral reflux disease.Type: ApplicationFiled: January 9, 2009Publication date: April 28, 2011Inventors: Christine Wallrapp, Herma Glöckner, Roland Reiner, Frank Thürmer
-
Publication number: 20110082076Abstract: Microparticle compositions comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compositions and methods of treating certain conditions and disease states by administering the microparticle compositions. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compositions of the present invention have superior stability to other microparticle compositions resulting in a microparticle composition with longer shelf life and improved dispersability. The microparticle compositions of the present invention have a transition temperature (Tg) of at least 20° C. above the recommended storage temperature (Tst) for drug delivery.Type: ApplicationFiled: December 14, 2010Publication date: April 7, 2011Applicant: NOVARTIS AGInventors: Luis A. Dellamary, Jean Riess, Ernest G. Schutt, Jeffry G. Weers, Thomas E. Tarara
-
Publication number: 20110076317Abstract: The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.Type: ApplicationFiled: September 21, 2010Publication date: March 31, 2011Inventors: Thomas R. Alessi, Kenneth L. Luskey
-
Publication number: 20110077200Abstract: A composition comprising doxepin, or a pharmaceutically acceptable salt, or prodrug thereof, and a compound that enhances sleep onset, sleep maintenance or reduces early morning awakenings. These compositions are useful for treating multiple manifestations of insomnia.Type: ApplicationFiled: December 6, 2007Publication date: March 31, 2011Applicant: SOMAXON PHARMACEUTICALS, INC.Inventors: Philip Jochelson, Robert Mansbach, Michael Skinner
-
Publication number: 20110070219Abstract: The present disclosure provides an effective method for the crystallization of proteins at high pressure. A preferential excluding agent, and optionally other reagents may be incorporated into the method. The method is applicable to substantially all proteins.Type: ApplicationFiled: April 27, 2010Publication date: March 24, 2011Inventors: Matthew B. SEEFELDT, Theodore W. Randolph, Ryan Crisman
-
Publication number: 20110071080Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.Type: ApplicationFiled: May 27, 2009Publication date: March 24, 2011Inventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle
-
Publication number: 20110045029Abstract: A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).Type: ApplicationFiled: February 23, 2010Publication date: February 24, 2011Applicant: ProCarrier, Inc.Inventors: Seung-Ho Choi, Seong-Wan Cho
-
Publication number: 20110033549Abstract: A dry composition for use in therapy or diagnosis, obtainable by drying an aqueous composition comprising a protein and one or more displacement buffers, wherein the pH of the aqueous composition is such that the protein is stable, wherein the or each displacement buffer has a pKa that is at least 1 unit greater or less than the pH of the aqueous composition, and wherein the aqueous composition is substantially free of a conventional buffer having a pKa that is within one pH unit of the pH of the aqueous composition.Type: ApplicationFiled: August 5, 2010Publication date: February 10, 2011Inventors: Jan Jezek, Charles Potter